Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Follow-Up Questions
IFTBF の株価パフォーマンスは？
IFTBF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Infant Bacterial Therapeutics AB の主な事業テーマや業界は？
Infant Bacterial Therapeutics AB は Pharmaceuticals 業界、セクターは Health Care に属しています。
Infant Bacterial Therapeutics AB の時価総額はいくらですか？
Infant Bacterial Therapeutics AB の現在の時価総額は $NaN です。
